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Cardiovascular disease (CVD) is the number one contributor to death in the 
United States and worldwide. Lipid risk markers for CVD include high serum 
concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), 
very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein (a), and triglyc-
erides, as well as low serum concentrations of high-density lipoprotein cholesterol 
(HDL-C). Additional factors to assess CVD risk include apolipoprotein A (associ-
ated with HDL) and apolipoprotein B (associated with LDL). A suggested dietary 
strategy to decrease these risk factors is to replace a portion of saturated fatty acids 
with unsaturated fatty acids – especially polyunsaturated fatty acids (PUFAs). One 
PUFA, in particular, is the essential omega-6 PUFA linoleic acid, which has been 
demonstrated to affect these CVD risk markers. Therefore, this chapter will discuss 
the effects of linoleic acid consumption on lipid risk markers for CVD in healthy 
individuals, the associated mechanisms, and dietary recommendations to decrease 
CVD risk.
Keywords: linoleic acid, fatty acids, lipid risk markers, cardiovascular disease, 
humans
1. Introduction
Cardiovascular disease (CVD) (includes heart disease and stroke) is the leading 
cause of death in the United States [1] and worldwide [2]. In the United States, heart 
disease is the number one contributor to death, causing 647,457 deaths (23% of total 
deaths), while stroke is the fifth leading cause of death, contributing to 146,383 
deaths (5.2% of total deaths) in 2017 [1]. Worldwide, heart disease is the leading 
cause of death, leading to 8.9 million deaths, or 16% of the total deaths globally in 
2019. Stroke is the second leading contributor to deaths worldwide, causing more 
than 6 million deaths, or 11% of the deaths, worldwide [2].
A suggested dietary strategy to decrease the risk factors for CVD is to replace a 
portion of saturated fatty acids (SFAs) with monounsaturated fatty acids (MUFAs) 
and polyunsaturated fatty acids (PUFAs) [3–10]. For example, the Nurses’ Health 
Study [11] demonstrated that replacing 5% of energy from SFAs with equivalent 
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energy from MUFAs, PUFAs, or carbohydrates from whole grains, decreased the 
risk for coronary heart disease (CHD). A meta-analysis of randomized controlled 
trials reported that replacing saturated fat with polyunsaturated fat reduced CHD 
events [12].
However, certain authors and publications are not in agreement with these 
recommendations to decrease the risk factors for CVD, cardiovascular events, 
and/or mortality [13–22]. The PURE prospective cohort study concluded that 
intakes of total, saturated, and unsaturated fats were not significantly associated 
with the risk of myocardial infarction or CVD mortality [23]. Meta-analyses 
of prospective cohort studies demonstrated that consumption of saturated fat 
was not associated with an increased risk of CVD [24]. Interestingly, there was 
an inverse association between saturated fat intake and the risk of stroke [25]. 
Additionally, a meta-analysis of randomized controlled trials reported that 
replacing saturated fat with primarily polyunsaturated fat is “unlikely” to reduce 
CVD events or mortality [26]. Hooper et al. [27], in a review of randomized 
controlled trials, stated that there is “little or no effect of reducing saturated fat 
on all-cause mortality or cardiovascular mortality.”
As noted, there is controversy regarding the effects of the consumption of fatty 
acids on CVD risk. One such controversy is the recommendation of linoleic acid, 
which is the essential omega-6 (or n-6) PUFA [28–30]. For example, it has been 
found that replacing saturated fat with linoleic acid lowers serum cholesterol, but 
does not lower the risk of death from CHD [21, 22]. Furthermore, there is concern 
regarding whether linoleic acid increases the risk for inflammation [31].
An analysis of prospective observational studies demonstrated that higher tissue 
and serum concentrations of linoleic acid decreased the risk for cardiovascular 
events [32]. The Cardiovascular Health Study, a prospective cohort study, discov-
ered that higher circulating linoleic acid concentrations reduced total and CHD 
mortality [33]. A meta-analysis of prospective cohort studies found that decreased 
consumption of omega-6 PUFAs and increased intakes of saturated and trans-
fatty acids increased CHD mortality [34]. Linoleic acid consumption reduced the 
risk of CHD events and death, according to another meta-analysis of prospective 
cohort studies [35]. A systematic review of randomized controlled trials, in which 
there was a replacement of dietary saturated and monounsaturated fatty acids 
with omega-6 fatty acids, concluded that omega-6 fatty acids lowered the risk of 
myocardial infarction. Additionally, the intake of omega-6 fatty acids reduced total 
serum cholesterol, but not “other blood fat fractions”. It was also highlighted that 
“the benefits of omega-6 fats remain to be proven” [36].
According to the diet-heart hypothesis, a high consumption of saturated fat 
and cholesterol – and a low intake of polyunsaturated fat – increase the build-up 
of cholesterol and plaques in artery walls; these developments, therefore, increase 
the risks for atherosclerosis, cardiovascular disease, and myocardial infarction 
[18, 21, 37] . However, the diet-heart hypothesis has been evolving, and thus, some 
individuals recommend focusing more on overall dietary patterns, rather than 
individual fatty acids [37]. Moreover, there are a variety of factors that contribute 
to increasing the risk for CVD, such as high blood pressure, arrhythmia, inflam-
mation, thrombosis, insulin resistance, endothelial dysfunction, obesity, cigarette 
smoke, genetics, the microbiome, a lack of exercise, a high alcohol consumption, 
and overall dietary patterns [14, 18, 37–42].
Lipid levels have also been proposed to be “strong” risk factors for CVD and 
mortality. These lipid risk factors include the following: high serum concentrations 
of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), 
lipoprotein(a), and very-low-density lipoprotein cholesterol (VLDL-C), as well 
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as low serum concentrations of high-density lipoprotein cholesterol (HDL-C). In 
addition, apolipoprotein A1 (associated with HDL) and apolipoprotein B (associ-
ated with LDL) have been used as CVD risk markers [18, 43]. Interestingly, LDL 
particle size has also been utilized as a risk marker for CVD. The small, dense LDL 
subclass, compared to large, buoyant LDL particles, has been reported to be more 
atherogenic [44–50].
Therefore, this chapter will focus on the consumption of linoleic acid on lipid 
risk markers for CVD in healthy individuals, such as total cholesterol, triglycerides, 
LDL-C, LDL particle size, lipoprotein(a), VLDL-C, HDL-C, apolipoprotein A1, and 
apolipoprotein B. The associated mechanisms of action will also be covered. The 
chapter will conclude with recommendations to decrease the risk factors for CVD. 
Significant dietary sources of linoleic acid are presented in Tables 1 and 2. The 
chemical structure of linoleic acid is illustrated in Figure 1.











Oil sources of linoleic acid (per 100 grams) [51, 52].











Linoleic acid content in nuts and seeds (per 1 ounce or 28.3495 grams) [51, 52].
Figure 1. 
The chemical structure of linoleic acid [53].
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2.  The effects of linoleic acid consumption on lipid risk markers for 
cardiovascular disease in healthy individuals
The consumption of linoleic acid has been demonstrated to affect lipid risk 
markers for cardiovascular disease. The discussed studies include intervention trials 
that investigated the effects of linoleic acid consumption, in grams or percentage of 
energy, on CVD lipid risk markers in healthy individuals. Therefore, epidemiologi-
cal, postprandial, and animal studies are not covered. The results are organized by 
the respective CVD lipid risk marker.
2.1 Total cholesterol
The consumption of linoleic acid decreased total cholesterol compared to a usual 
U.S. diet (high in saturated fat and cholesterol) [54], and diets high in SFAs [55] 
(including stearic acid [56] and palmitic acid [57]), MUFAs [58], or medium-chain 
fatty acids [59]. A high intake of alpha-linolenic acid, the essential omega-3 fatty 
acid, decreased cholesterol concentrations compared to the control diet with the 
same percentage of linoleic acid [60]. In contrast, no significant differences in total 
cholesterol were observed after linoleic acid consumption compared to diets con-
taining eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (omega-3 
fatty acids) [61, 62], alpha-linolenic acid [63], high and low amounts of linoleic 
acid [64], oleic acid (a MUFA) [65, 66], or stearic acid [66]. Interestingly, intakes of 
SFA- or linoleic acid-rich diets – both supplemented with EPA and DHA – produced 
no significant differences in cholesterol concentrations [67].
2.2 Triglycerides
The consumption of linoleic acid decreased triglycerides compared to diets with 
significant amounts of oleic acid [58], stearic acid [56], or medium-chain fatty acids 
[59]. Intakes of linoleic acid, supplemented with EPA and DHA, reduced triglycer-
ide concentrations versus a linoleic acid diet rich in oleic acid [62]. A SFA-rich diet 
and a diet high in linoleic acid, both with added EPA and DHA, lowered triglyceride 
concentrations, with no significant differences between diets [67]. In contrast, diets 
supplemented with EPA and DHA decreased triglycerides compared to linoleic acid 
intakes [55, 61]. No significant differences were observed regarding triglyceride 
concentrations between lower and higher linoleic acid intakes [54, 60, 64], and 
diets rich in linoleic acid versus diets high in alpha-linolenic acid [63], oleic acid 
[65], or stearic acid [66].
2.3 Low-density lipoprotein cholesterol (LDL-C)
Intakes of linoleic acid decreased LDL-C versus diets rich in oleic acid [58], 
SFAs [55], palmitic acid [57], stearic acid [56, 68], trans-fatty acids [68], or 
medium-chain fatty acids [59]. Furthermore, higher amounts of linoleic acid more 
significantly lowered LDL-C concentrations [54, 57]. There were mixed results or 
no significant differences in comparison to oleic acid [62, 65, 66, 68]. Additionally, 
there were no significant differences when comparing linoleic acid consumption 
to alpha-linolenic acid [63] or stearic acid [66]. Consuming low and high amounts 
of linoleic acid – along with significant amounts of alpha-linolenic acid [64] or 
EPA and DHA [62] – also did not differ. Moreover, no significant differences were 
observed with respect to LDL-C after following a SFA-rich diet or a diet high in 
linoleic acid – both supplemented with EPA and DHA [67].
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2.4 LDL particle size
There were no significant differences in LDL particle size after consumption 
of low and high amounts of linoleic acid [60, 69], and intakes of linoleic acid 
compared to oleic acid or stearic acid [66]. Interestingly, there were decreases in 
large and small LDL particle concentrations after 10 days of a linoleic acid-rich diet 
compared to a diet high in SFAs, with both diets supplemented with EPA and DHA 
[70]. In contrast, no significant differences were observed in LDL particle size after 
6 weeks of a linoleic acid-rich diet comparted to a SFA-rich diet (both supplemented 
with EPA and DHA) [67].
2.5 Very-low-density lipoprotein cholesterol (VLDL-C)
Following consumption of diets rich in linoleic acid, there were decreases in 
VLDL-C concentrations compared to diets containing significant amounts of oleic 
acid [58] or medium-chain fatty acids [59]. In contrast, intakes of a SFA- or linoleic 
acid-rich diet (both containing significant amounts of EPA and DHA) resulted in 
no significant differences between diets; however, both diets decreased VLDL-C 
concentrations [67].
2.6 High-density lipoprotein cholesterol (HDL-C)
HDL-C increased following consumption of linoleic acid compared to stearic 
acid [56]. In contrast, intakes of linoleic acid decreased HDL-C compared to EPA 
and DHA [61] or palmitic acid [57]. However, most studies noticed no signifi-
cant differences regarding HDL-C concentrations after consuming low and high 
amounts of linoleic acid [54, 60, 62, 64], and linoleic acid compared to oleic acid 
[58, 65, 66], alpha-linolenic acid [60, 63], or stearic acid [66]. Interestingly, intakes 
of SFAs or linoleic acid (both diets supplemented with EPA and DHA) displayed no 
significant differences in HDL-C concentrations [67].
2.7 Lipoprotein(a)
Linoleic acid consumption reduced lipoprotein(a) concentrations compared 
with a diet high in trans-fatty acids [68]. However, linoleic acid intake increased 
lipoprotein(a) compared to a diet rich in SFAs [55]. In contrast, no significant dif-
ferences were found after consuming linoleic acid compared to SFAs, oleic acid, or 
stearic acid [68].
2.8 Apolipoproteins A1, A2, and B
The consumption of linoleic acid increased apolipoprotein A1 compared to 
a typical U.S. diet [54]. Additionally, linoleic acid increased apolipoprotein A2 
compared to EPA and DHA [55]. In contrast, apolipoproteins A1 and A2 decreased 
after following a diet rich in linoleic acid compared to a diet high in oleic acid [65]. 
Apolipoprotein A1 concentrations did not differ when comparing low and high 
linoleic acid intakes [60], and consumption of linoleic acid compared to diets 
containing high amounts of stearic acid or oleic acid [66]. There were decreases in 
apolipoprotein B concentrations after linoleic consumption compared to a typical 
U.S. diet [54], stearic acid, elaidic acid (a trans-fatty acid) [56], or SFAs [55]. There 
were no significant differences with respect to apolipoprotein B after intakes of 
linoleic acid compared with oleic acid [65, 66] or stearic acid [66].
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3.  The mechanisms by which linoleic acid affects lipid risk markers for 
cardiovascular disease
Linoleic acid (or PUFAs) has been demonstrated to affect CVD lipid risk markers. 
The mechanisms involved in altering these risk markers will be discussed in this section.
3.1 Total cholesterol
PUFAs have been shown to increase liver X receptor alpha (LXRα) gene expres-
sion [71, 72] via peroxisome proliferator activated receptors (PPARs) [71]. LXRα 
stimulates the expression of cholesterol 7 α-hydroxylase (CYP7), thereby convert-
ing cholesterol to bile acids. Therefore, by increasing CYP7 activity, PUFAs partici-
pate in cholesterol catabolism [73].
3.2 Triglycerides
PUFAs interact more strongly with PPARα compared to SFAs [74]. PPARα binds 
to peroxisome proliferator response elements (PPREs) located in the promotor 
regions of genes, such as apoC-III and lipoprotein lipase (LPL) [75]. It has been 
proposed that LPL may demonstrate increased activity towards VLDL triglycerides 
containing polyunsaturated fatty acids, thereby leading to increased breakdown of 
triglyceride-rich lipoproteins (chylomicrons and VLDL particles) [73, 76, 77]. LPL 
activity is inhibited by apoC-III, and thus, increases triglyceride concentrations 
[78]. It has been reported that PUFAs decrease apoC-III, thereby increasing LPL 
activity and, indeed, VLDL catabolism [73]. Moreover, omega-3 PUFAs have been 
shown to reduce triglycerides by lowering diacylglycerol acyltransferase, fatty acid 
synthase, and acetyl coenzyme A (CoA) carboxylase [79–84].
3.3 LDL-C
Intakes of linoleic acid [85] or PUFAs [73] have been demonstrated to increase 
LDL receptor activity, protein, and mRNA compared to SFAs. Furthermore, PUFAs 
increase membrane fluidity [73, 85, 86], which increases LDL receptor activity, and 
thus, increases LDL catabolism [87–89].
3.4 LDL particle size
It has been reported that consumption of SFAs increases large, buoyant LDL 
particles compared to lower SFA-containing diets [69, 90], whereas consumption of 
diets rich in PUFAs decreases large, buoyant LDL particles versus diets high in SFAs 
[70, 91]. It has been suggested that SFAs increase LPL and hepatic lipase activities 
[92, 93]. As such, LPL increases large, buoyant LDL particles, whereas hepatic 
lipase may stimulate the catabolism of triglyceride-rich lipoprotein remnants [92]. 
However, additional research is needed in this area regarding the mechanisms by 
which individual fatty acids affect LDL particle size.
3.5 VLDL-C
The sterol regulatory element-binding protein-1 (SREBP-1) is associated with 
lipogenesis and cholesterol synthesis in the liver [94, 95]. PUFAs have been shown 
to inhibit SREBP-1 gene transcription and/or protein [96], thereby lowering VLDL 
secretion from the liver [73, 96]. In addition, intakes of PUFAs increase VLDL 
catabolism and uptake [59, 81].
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3.6 HDL-C
Replacing SFAs with MUFAs and/or PUFAs generates lower total cholesterol 
and LDL-C concentrations, with modest HDL-C reductions; however, a lower total 
cholesterol: HDL-C ratio results [4, 97]. It is thought that dietary fat increases the 
“transport rate” and decreases the “fractional catabolic rate” of HDL cholesterol 
ester and apolipoprotein A1 [98]. However, more research is needed to describe the 
mechanisms by which individual fatty acids impact HDL-C.
3.7 Lipoprotein(a)
Lipoprotein(a) is synthesized in the liver and contains apolipoprotein A, 
which is bound to apolipoprotein B-100 [99–101]. The biological activity of 
lipoprotein(a) is unknown [102]; however, high concentrations have been associ-
ated with CVD [101, 103, 104]. Genetics seem to be the primary determinant 
of lipoprotein(a) [105]. Hence, diet and exercise do not appear to be significant 
contributors to lipoprotein(a) concentrations. There have also been inconsistent 
findings of fatty acid consumption (including PUFAs) on lipoprotein(a) concen-
trations [106]. However, it has been suggested that fatty acids may affect liver 
apolipoprotein(a) synthesis, thereby impacting lipoprotein(a) [106–108]. As 
such, more research is needed to determine the effects of dietary composition on 
lipoprotein(a) concentrations.
3.8 Apolipoprotein A1
HDL particles contain apolipoprotein A1, which interacts with the ATP-binding 
cassette transporter on the surface of cells. Furthermore, apolipoprotein A1 is a 
cofactor for lecithin cholesterol acyl transferase, which generates mature HDL 
particles [43, 109]. Plasma apolipoprotein A1 concentration typically coincide with 
HDL-C concentrations [43]. The significance of apolipoprotein A2 is less clear 
[110]. Interestingly, PPARα also interacts with PPREs in the promoter region of the 
apolipoprotein A1 gene in the liver [75]. Hence, PUFAs may exert their effects on 
apolipoprotein A1 via PPARα [73].
3.9 Apolipoprotein B
Apolipoprotein B also occurs in two forms: apolipoprotein B-48 and apolipopro-
tein B-100. The intestine synthesizes apolipoprotein B-48, which is a component of 
chylomicrons. The liver produces apolipoprotein B-100, which is associated with 
VLDL and LDL particles. Apolipoprotein B is necessary for the binding of lipopro-
teins to the LDL receptor. Apolipoprotein B plasma concentrations are significantly 
associated with LDL-C concentrations [43, 111]. It has been reported that high 
apolipoprotein B concentrations increase the risk for CVD, whereas apolipoprotein 
A1 concentrations decrease CVD risk [43, 112]. As mentioned previously, PUFAs 
increase LDL catabolism, thereby reducing apolipoprotein B [87].
4. Linoleic acid recommendations
The adequate intake (AI) values for linoleic acid for males and females (19-50 years) 
are 17 grams/day and 12 grams/day, respectively. Regarding males and females ages 
51-70 years, the AI values for linoleic acid are 14 grams/day and 11 grams/day, respec-
tively. The American Heart Association recommends consuming 5 to 10% of energy as 
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linoleic acid to decrease CVD risk [29, 31]. Additionally, the World Health Organization 
recommends consuming 2.5 to 9% of energy from linoleic acid to decrease LDL and 
total cholesterol concentrations, and thus, lower the risk for CVD [113]. It is not recom-
mended to consume more than 10% of energy as linoleic acid due to limited research.
5. Fat recommendations
In addition to linoleic acid recommendations, there are fat recommendations 
to reduce CVD risk, cardiovascular events, and/or mortality. For example, it has 
been suggested to replace approximately 5% of energy from SFAs with MUFAs 
and/or PUFAs [4, 8–12, 38, 113], and to consume less than 10% of energy as 
SFAs [113, 114]. On the other hand, certain studies do not coincide with these 
recommendations [14–17, 21–27, 115]. In addition, low-fat, and in-turn, high-
carbohydrate diets, decrease LDL-C; however, there is also a reduction in HDL-C 
and increased concentrations of VLDLs or triglycerides [37, 97, 116–118], which 
may produce higher amounts of small, dense LDL particles [41, 119, 120]. It 
has been reported that higher-fat versus lower-fat diets increase large, buoyant 
LDL and/or decrease small, dense LDL particles [69, 92, 121–123] . Interestingly, 
higher SFA intakes also increase large LDL and/or decrease small LDL particles 
[69, 90, 124–126]. These small, dense LDL particles may increase the risk for CVD 
in the following ways: 1) increased transport into arterial walls [127]; 2) increased 
attachment to proteoglycans [128]; 3) increased oxidation [129, 130]; and 4) 
reduced binding to the LDL receptor [127, 131, 132].
Various organizations have published dietary recommendations to decrease 
the risk factors for CVD. The American College of Cardiology/American Heart 
Association Task Force suggests consuming a diet rich in fruits, vegetables, whole 
grains, nuts, legumes, lean animal or plant protein sources, and fish. Additionally, 
it is recommended to decrease the consumption of red and processed meats, refined 
carbohydrates, trans-fatty acids, sodium, cholesterol, and sugar-sweetened drinks 
[38]. The Dietary Guidelines for Americans suggest consuming vegetable oils to 
replace sources rich in SFAs, such as butter, shortening, lard, palm oil, palm kernel 
oil, coconut oil, full-fat dairy products, and high-fat meats [114]. The World Health 
Organization also recommends replacing SFAs with unsaturated fatty acids, such as 
sunflower, safflower, corn, soybean, canola, and olive oils, as well as nuts, avocado, 
and fish [113].
It has been recently proposed, however, that guidelines to lower the risk for 
CVD should focus on overall dietary patterns, rather than individual fatty acids 
[14, 133]. The consumption of low-fat diets, for example, did not reduce CVD risk 
[134, 135]. Furthermore, certain individuals with higher intakes of saturated fat 
and cholesterol do not possess high CVD mortality rates, as they have an increased 
consumption of plant foods – in addition to MUFAs and PUFAs [15]. Furthermore, 
some foods that are higher in SFAs have not been demonstrated to increase the risk 
for CVD. A proposed explanation for these outcomes is the food matrix of these 
items, such as macro- and micronutrients, phytochemicals, and probiotics [14, 37].
6. Conclusions
This chapter focused on the effects of linoleic acid consumption on lipid risk 
markers for CVD in healthy individuals. Interestingly, linoleic acid reduced total 
cholesterol and LDL-C compared to diets that were lower in PUFAs and/or higher in 
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SFAs. In contrast, linoleic acid generated inconsistent outcomes regarding triglycer-
ides, whereas EPA and DHA more significantly reduced triglyceride concentrations. 
In limited studies, linoleic acid decreased VLDL-C compared to diets containing 
oleic acid or medium-chain fatty acids, and decreased HDL-C compared to palmitic 
acid or EPA and DHA; however, linoleic acid increased HDL-C compared with 
stearic acid. Additionally, linoleic acid reduced apolipoprotein B in comparison to 
a typical U.S. diet, SFAs, or trans-fatty acids. Interestingly, there were inconsistent 
Figure 2. 




results or no significant differences for selected CVD lipid risk markers – particu-
larly when comparing linoleic acid to oleic acid. Therefore, additional research is 
needed regarding the effects of fatty acids on markers that increase the risk for 
CVD – in addition to the associated mechanisms.
The development of CVD is a complex process which involves many factors that 
influence the discussed lipid risk markers, such as exercise patterns, overweight/
obesity, cigarette smoke, hypertension, high alcohol consumption, and genetics. To 
add to this complexity is our dietary patterns. As discussed, there are mixed results 
regarding the consumption of linoleic acid on CVD lipid risk markers. One such 
dietary explanation is the complex food matrices of these items, which may, there-
fore, influence CVD risk markers. In other words, we do not consume individual 
fatty acids; we consume food. For example, individual saturated and unsaturated 
fatty acids have differing effects on CVD risk markers; however, these individual 
effects may be diminished when these fatty acids are components of whole food 
items. This attribute may explain, in part, for the differing outcomes of saturated 
and unsaturated fat on CVD risk, events, and/or mortality. Perhaps, therefore, we 
should focus on whole foods and overall dietary patterns when providing guidelines 
to reduce the risk for CVD.
It is recommended that future studies investigate the effects of various dietary pat-
terns on CVD risk markers, such as lower-carbohydrate versus higher-carbohydrate 
diets, lower-fat versus higher-fat diets, and plant-based versus meat-based diets. 
Based on the heterogeneity of the reviewed studies on the effects of linoleic acid 
consumption on lipid risk markers for CVD, future studies should be longer in dura-
tion – with more participants. Moreover, it should be clarified, in future publications, 
whether the discussed CVD lipid risk markers exist as strong and independent risk 
factors for CVD.
It is clear that the consumption of fat is a critical component to a healthy diet; 
consuming too much or too little can have detrimental effects on one’s health. 
Therefore, moderation is an important factor to keep in mind regarding fat 
consumption. It seems, however, that certain dietary recommendations focus on 
decreasing the intakes of saturated fatty acids, and increasing the consumption of 
monounsaturated and polyunsaturated fatty acids. These recommendations may 
not be optimal in the following ways: 1) foods consist of individual fatty acids, 
which have different effects on CVD lipid risk markers; 2) overall dietary patterns 
and food components may offset the effects of specific fatty acids; and 3) individu-
als may not be familiar with significant food sources of saturated, monounsatu-
rated, and polyunsaturated fatty acids. Therefore, it seems that dietary guidelines 
to lower the risk for CVD should focus on overall dietary patterns, rather than 
individual fatty acids (Figure 2).
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